Every article, presentation, spotlight, and news item we've tagged to Therapies and Protocols.
Discover how electromagnetic pulses recharge your cells' natural voltage, enhancing nutrient transport and accelerating recovery. Nearly two decades of PEMF innovation supporting millions worldwide.
Hyperbaric oxygen therapy leverages a simple physics principle to deliver oxygen deep into tissues where recovery and repair demand it most. Here's how increased pressure supports cellular energy, circulation, and regeneration, and where it fits in a whole-system longevity strategy.
PEMF therapy addresses cellular energy production by restoring optimal bioelectric function, offering a research-backed approach to enhanced vitality and recovery.
Dr. Jason Sonners reveals how hyperbaric oxygen therapy fundamentally transforms cellular recovery through the physics of pressure. Drawing on 17 years of clinical experience and current PhD research in molecular biology, he demystifies how pressurized oxygen bypasses normal physiological limits to deliver therapeutic benefits unavailable through any other modality. This session breaks down the molecular mechanisms behind HBOT's effects on ATP production, stem cell mobilization, inflammation reduction, and tissue regeneration—explaining why this underutilized therapy deserves a central role in performance optimization and longevity protocols.
Your mitochondria contain light-sensitive proteins that trigger cellular repair and energy production when exposed to specific infrared wavelengths. Modern indoor living has created a light deficiency that affects everything from energy to immunity.
Discover how combining PEMF therapy with sound frequencies can restore cellular resonance, supporting everything from mitochondrial function to nervous system regulation in a practical home-use system.
Stanford neurobiology professor Andrew Huberman delivers a masterclass on the vagus nerve, revealing how this extensive neural pathway controls everything from mood to alertness to learning capacity. Drawing from cutting-edge neuroscience research at Huberman Lab, this session explores the precise anatomy and dual sensory-motor functions of cranial nerve 10. Huberman demonstrates how understanding the vagus nerve's connections throughout the body—from brain to pelvis—unlocks actionable tools for achieving peak performance states, enhanced neuroplasticity, and optimized health without pharmaceuticals or devices.
Vagal tone is a measurable, trainable capacity that influences HRV, stress recovery, and longevity. Ultrasound-based vagus nerve stimulation offers a new approach to parasympathetic training, and the foundations you build around it matter most.
Discover how acoustic frequencies can restore your body's natural rhythms without EMF exposure. WAVwatch delivers 166 targeted sound therapy programs through skin contact for energy, sleep, and recovery.
Your brain cycles through distinct electrical states every day, and how smoothly it transitions between them affects everything from sleep quality to cognitive sharpness. Brainwave entrainment, paired with light therapy, offers a structured way to train that flexibility.
Recent research reveals how specific wavelengths of red and near-infrared light can enhance the gut-brain axis by boosting mitochondrial ATP production, supporting both mental clarity and digestive comfort through targeted cellular energy optimization.
Discover the revolutionary intersection of red light therapy and gut-brain health with CeraThrive CEO Sarah Turner. Drawing from her extensive background in clinical neuroscience and photobiomodulation research, Sarah unveils breakthrough applications of near-infrared light therapy for optimizing the gut-brain axis. Learn how her FDA-listed CERA System and cutting-edge photobiomodulation protocols can enhance cognitive function, support digestive health, and unlock new pathways to longevity through targeted light-based interventions.
Discover why measuring intracellular NAD+ levels transforms guesswork into precision optimization, helping you maintain cellular energy and vitality decades longer.
Restore Hyper Wellness is promoting NAD supplementation through IV and intramuscular delivery formats, capitalizing on significant year-over-year increases in consumer search interest for NAD-related therapies. The initiative positions NAD precursors and direct NAD administration as tools for cellular energy optimization, though clinical evidence supporting broad longevity claims remains limited.
NAD+ delivery methods—pills, injections, and pens—are receiving increased clinical scrutiny as the molecule transitions from niche longevity therapy to mainstream wellness category. The effectiveness of NAD+ depends less on the molecule itself than on bioavailability, formulation quality, and whether patients maintain consistent use.
Niagen Bioscience launched a prescription-only telehealth platform delivering subcutaneous NAD+ injections at home, shifting nicotinamide riboside from over-the-counter supplement to clinician-directed pharmaceutical intervention. The model combines telehealth access with clinical oversight and compounded pharmaceutical-grade dosing, though the clinical evidence supporting NAD+ supplementation for meaningful longevity outcomes remains incomplete.
Hyperbaric oxygen therapy, traditionally confined to clinical medicine, is being deployed in performance and longevity settings through chambers like ZEUGMA, which operate at pressures enabling oxygen to dissolve into plasma at concentrations far exceeding atmospheric levels. The mechanism addresses tissue oxygen delivery and cellular repair, though evidence for durable benefits in healthy individuals remains under investigation.
Nuchido addresses NAD+ decline through targeted restoration of the salvage pathway rather than simple precursor replacement, supported by randomized controlled human trials demonstrating improvements in inflammation, glycation, and biological age markers. This systems-biology approach represents a maturation of the NAD+ intervention landscape toward mechanistic rather than marketing-driven solutions.
VoxNeuro received FDA 510(k) clearance for software that analyzes brain electrical activity through standardized cognitive tasks, providing clinicians with quantified measures of neural function against a reference database of nearly 20,000 healthy adult data points. The tool supports assessment of cognitive processing without delivering diagnosis, positioning it as an objective biomarker for brain function relevant to early detection and monitoring.
Niagen Bioscience launched Niagen Plus, a telehealth platform delivering prescription-only nicotinamide riboside (Niagen) via at-home subcutaneous injection. The injectable route is positioned to bypass first-pass hepatic metabolism and improve tissue bioavailability compared to oral administration.
Light-activated photodynamic therapy for cutaneous T-cell lymphoma demonstrates a treatment design principle critical to chronic disease management: therapies must be engineered for decades of safe, repeatable use rather than optimized solely for efficacy. For conditions that persist across a lifespan, cumulative toxicity and patient burden become as clinically significant as the primary disease.
Psilocybin demonstrates measurable effects on lifespan and healthspan markers in preclinical models, operating through neuroplasticity pathways and stress-response modulation. The compound's capacity to alter consciousness-linked neural signaling raises questions about its role in longevity pathways previously associated with psychological resilience and systemic stress tolerance.
Renue by Science received recognition for its Total NAD+ Restoration Protocol, a multi-pathway supplement approach designed to address age-related NAD+ decline through enhanced precursor delivery, reduced NAD+ catabolism, improved mitochondrial efficiency, and cellular repair support. NAD+ restoration represents a targeted intervention in the metabolic foundation of cellular aging.
QuantalX Neuroscience has launched Delphi MD, an FDA-cleared non-invasive system that quantifies real-time functional brain network activity using transcranial magnetic stimulation, electroencephalography, and AI analytics. This technology enables clinicians to detect subtle changes in brain function before structural damage or cognitive decline becomes apparent, shifting neurological care from reactive symptom management to preventive assessment.
Aging and Western diet consumption jointly impair thyroid hormone metabolism in the liver through altered deiodinase enzyme activity, depleting active thyroid hormone at the cellular level and accelerating fatty liver disease progression. Restoring thyroid hormone signaling reverses senescence markers and reduces inflammation, identifying a therapeutic pathway for metabolic liver disease in aging populations.
Osteoboost has secured $8 million in funding to scale an FDA-cleared wearable device that delivers calibrated vibration therapy to address osteopenia, a condition affecting 44 million Americans currently managed with minimal intervention. The device represents a regulated approach to early-stage bone loss prevention in a market where pharmacological treatment remains absent and diagnostic management remains largely passive.
Jupiter Neurosciences acquired exclusive US rights to ALA-002, a clinical-stage psychedelic therapy for treatment-resistant PTSD and severe anxiety, signaling a strategic shift in longevity medicine toward brain-centered approaches. The deal reflects growing recognition that neurological health and trauma recovery may be foundational to aging biology itself.
i-Lumen Scientific has enrolled the first U.S. patient in i-SIGHT2, a pivotal trial testing bioelectric microcurrent stimulation delivered through the eyelid to restore retinal function in intermediate to advanced dry age-related macular degeneration. The therapy aims to repolarize retinal pigment epithelium cells and improve photoreceptor function, addressing a condition with limited treatment options.
The FDA granted Breakthrough Device Designation to CorTec's Brain Interchange, a fully implantable wireless brain-computer interface that uses closed-loop neural recording and adaptive stimulation to restore motor function in chronic stroke patients. Early clinical data show meaningful upper-limb recovery in patients whose progression had plateaued under conventional therapy.
AEON Clinic has launched ExoMind, an integrated treatment program combining clinical assessment, neuromodulation, and psychotherapy for treatment-resistant mental health conditions including OCD, ADHD, and PTSD. The program lacks published clinical trial data or specified regulatory clearances, positioning it as a personalized approach to conditions poorly managed by standard therapies.
Psychedelics show promise for cognitive resilience and neural regeneration, but Schedule I classification creates regulatory barriers that prevent clinical investigation of their healthspan applications. Current drug policy frameworks were designed for acute disease endpoints and cannot adequately evaluate interventions targeting age-related decline over extended timeframes.
I-Lumen Scientific received FDA approval to expand enrollment of i-SIGHT2, a clinical trial evaluating non-invasive bioelectric stimulation for intermediate to advanced dry age-related macular degeneration. The therapy aims to restore retinal function through microcurrent stimulation of the retinal pigment epithelium, with U.S. enrollment beginning in late April 2026.
NKGen Biotech is advancing Troculeucel, an autologous natural killer cell therapy, through Phase 2 trials for Alzheimer's disease with expansion into other neurodegenerative conditions. The approach targets immune system dysfunction in neurodegeneration, representing a distinct mechanistic pathway from conventional pharmacological interventions.
AnHorn Medicines has initiated a Phase 1 trial of AH-008, a first-in-class neuroprotective agent designed to prevent chemotherapy-induced peripheral neuropathy by targeting neuroinflammatory pathways before irreversible nerve damage occurs. Since 60–70% of chemotherapy patients develop CIPN and one-third experience persistent symptoms beyond six months with no approved preventive options, this intervention addresses a significant clinical gap in cancer supportive care.
TreeFrog Therapeutics reports that TFG-001, a 3D neural microtissue therapy, achieves dopamine release within 48 hours and accelerates motor recovery in Parkinson's models to approximately 13 weeks—4 to 15 weeks faster than existing cell therapies. The advancement addresses a critical gap in neurodegeneration treatment by improving graft integration and functional reinnervation.
NeuroEM Therapeutics appointed Dr. W. Scott Burgin as Chief Medical Officer to advance its transcranial electromagnetic treatment technology for Alzheimer's disease and cognitive decline. The non-drug approach uses wearable devices to modulate neuronal activity and holds FDA Breakthrough Device designation, positioning it as a potential alternative to pharmaceutical interventions in neurodegeneration.
Kenai Therapeutics completed enrollment in its Phase 1b/2a REPLACE trial of RNDP-001, an off-the-shelf cell therapy designed to replace dopamine-producing neurons lost to Parkinson's disease rather than merely compensate for their absence. This approach represents a fundamental shift from symptomatic management toward actual neural regeneration, with potential implications for how neurodegenerative diseases are treated.
